Rydex Biotechnology Fund Class Investor (RYOIX)
| Fund Assets | 136.15M |
| Expense Ratio | 1.40% |
| Min. Investment | $2,500 |
| Turnover | 79.00% |
| Dividend (ttm) | 9.41 |
| Dividend Yield | 12.22% |
| Dividend Growth | -0.18% |
| Payout Frequency | n/a |
| Ex-Dividend Date | Dec 16, 2025 |
| Previous Close | 76.34 |
| YTD Return | 2.89% |
| 1-Year Return | 27.84% |
| 5-Year Return | 14.58% |
| 52-Week Low | 49.39 |
| 52-Week High | 78.56 |
| Beta (5Y) | n/a |
| Holdings | 77 |
| Inception Date | Apr 1, 1998 |
About RYOIX
Rydex Biotechnology Fund Class Investor is an actively managed mutual fund focused on the biotechnology sector. Its primary objective is to achieve capital appreciation by investing at least 80% of its net assets in equity securities of U.S.-traded biotechnology companies, leveraging both direct equity investments and derivatives such as futures contracts and options. The fund is non-diversified, allowing for a concentrated approach that can include significant positions in small to mid-sized biotechnology firms. This structure enables the fund to target growth opportunities within an industry known for innovation in medical research, pharmaceuticals, and life sciences. Managed by Security Investors, LLC since its inception in 1998, the fund plays a specialized role in the market by providing investors targeted access to biotechnology’s dynamic growth prospects, as well as exposure to the risks and rewards inherent in sector-specific strategies. It distributes capital gains annually and offers a relatively low entry point for individual investors, making it accessible for those seeking focused exposure to biotechnology advancements and trends.
Performance
RYOIX had a total return of 27.84% in the past year, including dividends. Since the fund's inception, the average annual return has been 14.02%.
Equivalent Funds
These are funds that follow the same index from the other major fund companies.
| Symbol | Provider | Name | Expense Ratio |
|---|---|---|---|
| FIKCX | Fidelity | Fidelity Advisor Health Care Fund - Class Z | 0.59% |
| FSPHX | Fidelity | Fidelity Select Health Care Portfolio | 0.63% |
| FIJYX | Fidelity | Fidelity Advisor Biotechnology Fund - Class Z | 0.61% |
| FACDX | Fidelity | Fidelity Advisor Health Care Fund - Class A | 0.98% |
| FSHCX | Fidelity | Fidelity Select Health Care Services Portfolio | 0.67% |
Top 10 Holdings
36.83% of assets| Name | Symbol | Weight |
|---|---|---|
| AbbVie Inc. | ABBV | 7.53% |
| Amgen Inc. | AMGN | 4.96% |
| Gilead Sciences, Inc. | GILD | 4.49% |
| Vertex Pharmaceuticals Incorporated | VRTX | 4.41% |
| Regeneron Pharmaceuticals, Inc. | REGN | 3.65% |
| Alnylam Pharmaceuticals, Inc. | ALNY | 2.90% |
| Insmed Incorporated | INSM | 2.32% |
| Natera, Inc. | NTRA | 2.27% |
| AstraZeneca PLC | AZN | 2.22% |
| Biogen Inc. | BIIB | 2.09% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 16, 2025 | $9.40578 | Dec 16, 2025 |
| Dec 12, 2024 | $9.42277 | Dec 12, 2024 |
| Dec 20, 2022 | $0.89943 | Dec 20, 2022 |
| Dec 8, 2021 | $15.77303 | Dec 8, 2021 |
| Dec 9, 2020 | $6.95038 | Dec 9, 2020 |
| Dec 10, 2019 | $3.60206 | Dec 10, 2019 |